bluuebunny/crossref_metadata_2025_split huggingface dataset:
Secundarismo sifilítico: un amplio espectro de manifestaciones dermatológicas
Authors: Cuellar Rios Isabel Cristina , Ávila Fedy , Lozano Alejandra 
Published: December 2017

<p><strong>Resumen</strong></p><p>El artículo describe el caso de un paciente de 28 años de edad con antecedente de VIH, quien presentaba múltiples lesiones en la piel y las mucosas, producto de sífilis secundaria, y quien mostraba un amplio espectro de manifestaciones cutáneas características de esta enfermedad. </p>
Full-Length Genome Sequence of Japanese Encephalitis Virus Strain FC792, Isolated from Guangxi, China
Authors: Lu Bingxia , Qin Yibin , Li Bin , He Ying , Duan Qunpeng , Liang Jiaxing , Chen Zhongwei , Su Qianlian , Bi Bingfen , Zhao Wu 
Published: December 2017

ABSTRACT
We report here the complete genomic sequence of Japanese encephalitis virus (JEV) strain FC792, isolated from aborted fetuses of sows which were unimmunized with JEV vaccines in Guangxi Province, southern China. The complete JEV genome of strain FC792 had the highest nucleotide homology (99.7%) and amino acid identity (99.4%) with the sequence of JEV strain SA14-14-2 (GenBank accession number AF315119). Phylogenetic analysis showed that strain FC792 had the closest phylogenetic relationship to the sequence of strain YUNNAN0901 (GenBank accession number JQ086762). This study will help us understand the molecular pathogenesis and genetic diversity of genotype III Japanese encephalitis virus in pigs.
Complete Genome Sequence of Bacillus velezensis L-1, Which Has Antagonistic Activity against Pear Diseases
Authors: Sun Pingping , Cui Jianchao , Jia Xiaohui , Wang Wenhui 
Published: December 2017

ABSTRACT

Bacillus velezensis
L-1 is an effective biocontrol agent against pear diseases. Here, we report the complete genome sequence of
B. velezensis
L-1 in which clusters related to the biosynthesis of secondary metabolites were predicted. This genome provides insights into the possible biocontrol mechanisms and furthers application of this specific bacterium.
Draft Genome Sequence of Alcaligenes faecalis BDB4, a Polyaromatic Hydrocarbon-Degrading Bacterium Isolated from Crude Oil-Contaminated Soil
Authors: Singha L. Paikhomba , Kotoky Rhitu , Pandey Piyush 
Published: December 2017

ABSTRACT

Alcaligenes fecalis
BDB4 was isolated from crude oil-contaminated soil in India. The genome sequence of
A. faecalis
BDB4 revealed the presence of important genes required for polyaromatic hydrocarbon (PAH) metabolism and other associated functions, such as chemotaxis, membrane transport, and biofilm formation, giving insight into the complete PAH mineralization potential of this bacterium.
Complete Genome Sequence of Bacillus velezensis YJ11-1-4, a Strain with Broad-Spectrum Antimicrobial Activity, Isolated from Traditional Korean Fermented Soybean Paste
Authors: Lee Hyo Jung , Chun Byung-Hee , Jeon Hye Hee , Kim Yeon Bee , Lee Se Hee 
Published: December 2017

ABSTRACT

Bacillus velezensis
YJ11-1-4 is a strain that exhibits broad-spectrum antimicrobial activity against various pathogens. It was isolated from doenjang, a traditional Korean fermented soybean paste. The genome comprises a single circular chromosome of 4,006,637 bp with 46.42% G+C content without plasmids.
Draft Genome Sequence of Vibrio splendidus DSM 19640
Authors: Chibani Cynthia Maria , Poehlein Anja , Roth Olivia , Liesegang Heiko , Wendling Carolin Charlotte 
Published: December 2017

ABSTRACT

Here, we present the draft genome sequence of
Vibrio splendidus
type strain DSM 19640.
V. splendidus
is an abundant species among coastal vibrioplankton. The assembly resulted in a 5,729,362-bp draft genome with 5,032 protein-coding sequences, 6 rRNAs, and 117 tRNAs.
Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study
Authors: Kawai Takashi , Oda Kazunori , Funao Nobuo , Nishimura Akira , Matsumoto Yasushi , Mizokami Yuji , Ashida Kiyoshi , Sugano Kentaro 
Published: December 2017

ObjectiveCompare efficacy and safety of vonoprazan and lansoprazole for secondary prevention of low-dose aspirin (LDA)-associated peptic ulcers in a 24-week study and long-term extension therapy in separate study.DesignDouble-blind, randomised, non-inferiority study; single-blind extension study at 104 Japanese sites, including 621 patients (439 in extension) with a history of peptic ulcers who required long-term LDA therapy. Randomised (1:1:1, computer generated) patients received lansoprazole 15 mg (n=217), vonoprazan 10 mg (n=202) or vonoprazan 20 mg (n=202) once daily for 24 weeks (double blind) and ≤2 years (extension). The following measurements were made: 24-week (primary outcome; double blind) and 12-week peptic ulcer recurrence rate, 24-week GI bleeding rate, cumulative incidences of peptic ulcer recurrence and GI bleeding, treatment-emergent adverse events, laboratory results, serum gastrin and pepsinogen I/II concentrations.ResultsThe 24-week peptic ulcer recurrence rate was 2.8%, 0.5% and 1.5% in the lansoprazole 15 mg, vonoprazan 10 mg and vonoprazan 20 mg groups, respectively. Vonoprazan was non-inferior (Farrington and Manning test: margin 8.7%, significance level 2.5%) to lansoprazole. In the post hoc analyses of the extension study, peptic ulcer recurrence rates were significantly lower with vonoprazan 10 mg (log-rank test, P=0.039), but not vonoprazan 20 mg (P=0.260), compared with lansoprazole 15 mg. GI bleeding rates were higher with lansoprazole compared with two doses of vonoprazan in both 24-week study and extension study.ConclusionVonoprazan (10 and 20 mg) was as effective as lansoprazole (15 mg) in preventing peptic ulcer recurrence during LDA therapy, had a similar long-term safety profile and was well tolerated.Trial registration numbersNCT01452763; NCT01456247.
No Association of Waist Circumference and Prostate Cancer in the Cancer Prevention Study II Nutrition Cohort
Authors: Stevens Victoria L. , Jacobs Eric J. , Maliniak Maret L. , Patel Alpa V. , Gapstur Susan M. 
Published: December 2017

Abstract
Background: The relationship between excess body weight and prostate cancer risk is unclear. However, some evidence suggests that waist circumference, which provides a measure of central adiposity, may be positively associated with more advanced stages or grades of prostate cancer.
Methods: The association between waist circumference and prostate cancer was investigated among 46,094 men enrolled in the Cancer Prevention Study II Nutrition Cohort, of whom 5,711 were diagnosed with this cancer between 1997 and 2013. Using Cox proportional hazards regression, we examined associations of weight circumference with total and high-grade prostate cancer incidence and with prostate cancer mortality.
Results: In both categorical and continuous analyses, waist circumference was not associated with total or high-grade (Gleason score ≥ 8) prostate cancer incidence or with prostate cancer mortality regardless of whether body mass index was adjusted for in the statistical model. Waist circumference was inversely associated with low-grade (Gleason score &lt; 8) prostate cancer, but the association was not statistically significant after adjustment for body mass index.
Conclusions: Our results suggest that central adiposity, as measured by waist circumference, is not significantly associated with prostate cancer incidence or mortality.
Impact: Compared with men in other studies with significant results, men in our study were considerably older, suggesting that age may influence the association between waist circumference and prostate cancer. Cancer Epidemiol Biomarkers Prev; 26(12); 1812–4. ©2017 AACR.
Abstract A20: Genomic study of KRAS/NRAS mutations of metastatic colorectal cancer in eastern Algeria
Authors: Mazouzi Khaoula 
Published: December 2017

Abstract
Background: Biological advances made a big lap in the treatment of metastatic patients where several therapeutic options are now available for patients based on research of gene. For colorectal cancer, it is essential to test KRAS-BRAF-NRAS mutations before starting any treatment and it is known in the literature that these mutations are found in approximately 45% of patients, that what made us thinking about analyzing the results of our patients' mutational tests.
Methods: It is a Prospective study that aims to analyze the KRAS/NRAS mutational profile of metastatic colorectal cancer patients treated at CHU Constantine-Anti Cancer Center during the period of January 2014 - August 2016. The molecular study includes: codon 12 and 13 of exon 2, codons 59 and 61 of exon 3 and codons 117 and 146 of exon 4 of K-Ras gene. The exons 2, 3 and 4 for the N-Ras gene have also been tested and no molecular testing has been done for B-RAF mutation. The search for mutations was performed by the Allele Specific PCR technique and a second confirmation by sequencing was done.
Results: 490 patients with colorectal cancer were registered; 34.69% were presented with metastases, of which 61, 17% are men and 38, 82% women. The extremes of age is 27 to 77 years, the average age is 52.6 years. 67.64% of these tumors have colic origin, 28.82% of rectal origin 3.52% from the recto sigmoidal junction. The histological presentation is: 95.29% adenocarcinoma [57.40% well differentiated, 37.03% moderately differentiated, 2.46% poorly differentiated and 3.08% are undifferentiated], 2.35% are adenocarcinomas with colloid component and 2.35% are independent cell carcinomas. 42.94% were wild type, 51.17% are mutated and 5.88% remained without status given the small quantity of DNA available for testing (not sufficient DNA) and the impossibility of re-biopsy.
The mutational profile for K-Ras gene was: 94.5% mutated in exons 2 with 76.82% in codon 12 and 23.17% in codon 13. 3.44% had mutations exons 3 without any detail of codons mentioned and 2.29% had rare mutations in the N-Ras gene without any extensive information.
Conclusion: The analysis of data find that the mutational profile of our patients is different than the profile presented in the literature, therefore, extensive molecular and genetic studies should be conducted in our area in search of explanations and in the hope of future therapeutic implications.
Citation Format: Khaoula Mazouzi. Genomic study of KRAS/NRAS mutations of metastatic colorectal cancer in eastern Algeria [abstract]. In: Proceedings of the AACR International Conference: New Frontiers in Cancer Research; 2017 Jan 18-22; Cape Town, South Africa. Philadelphia (PA): AACR; Cancer Res 2017;77(22 Suppl):Abstract nr A20.
Abstract B25: Sometimes it's spiritual: A mixed-methods study of cervical cancer stigma among women in Ghana, West Africa
Authors: Williams Michelle Sharonda , Kenu Ernest 
Published: December 2017

Abstract
Cervical cancer is the leading cause of cancer death among women in Ghana, West Africa. Previous studies have found that many Ghanaian women hold stigmatizing beliefs about cervical cancer, which may lead them to minimize their perceived susceptibility to the disease and reduce their perceived need for preventive cervical cancer screenings. The purpose of this study was to assess cervical cancer stigma among Ghanaian women and determine if there is a difference in the level of cervical cancer stigma among nurses and non-healthcare providers. The PEN-3 model provided the framework for this study. A convergent parallel mixed methods study design was used to conduct this study; therefore the study was divided into two strands, the quantitative strand and the qualitative strand. For the quantitative strand, 298 women who were recruited from public venues in Accra, completed a questionnaire containing items from the global cancer stigma index scale. For the qualitative strand, in-depth interviews were conducted with 21 nurses who worked in a large public hospital in Accra and 21 nurses who worked in a small private hospital in Battor. A semi-structured interview guide was used to assess cervical cancer stigma among the nurses. Univariate and bivariate analyses were preformed to explore the quantitative data. The qualitative data were analyzed using open coding and focused coding. The results of the quantitative and qualitative data analyses indicated that stigmatizing beliefs about cervical cancer were reported by nurses and women in the general population who were not healthcare providers. However, stigmatizing beliefs such as Women with cervical cancer are responsible for causing their own cancer, Women with cervical cancer are sexually easy, and Only promiscuous women need to have a regular cervical cancer screening were reported more frequently by women who were not healthcare providers. The results of this study can be used to inform the development of culturally-relevant cervical cancer stigma reduction interventions. Reducing cervical cancer stigma may lead to an increase in the number of Ghanaian women who seek regular, preventive cervical cancer screenings.
Citation Format: Michelle Sharonda Williams, Ernest Kenu. Sometimes it's spiritual: A mixed-methods study of cervical cancer stigma among women in Ghana, West Africa [abstract]. In: Proceedings of the AACR International Conference: New Frontiers in Cancer Research; 2017 Jan 18-22; Cape Town, South Africa. Philadelphia (PA): AACR; Cancer Res 2017;77(22 Suppl):Abstract nr B25.
Abstract A08: in vivo CRISPR screening enables precision medicine by identifying novel drug combinations and modeling anticancer drug sensitivity
Authors: ADLI Mazhar 
Published: December 2017

Abstract
Identifying novel targets to synergistically improve the efficacy of existing chemotherapy is a major goal in cancer research. Here, we report in vivo CRISPR knockout (KO) screening in a patient derived xenograft (PDX) model of pancreatic cancer to identify genes that mediate the resistance to trametinib, an inhibitor of the MEK signaling pathway, which is aberrantly active in pancreatic cancers due to oncogenic KRAS mutations. The screening and subsequent genetic as well as in vitro and in vivo pharmacological validations identified a set of kinetochore function genes whose depletion is synthetic lethal with MEK inhibition. by triggering mitotic slippage and polyploidy. Notably, using the unbiased knowledge of gene-specific survival scores from the in vivo KO screening under the pressure of a chemotherapeutic agent, we devised a novel Drug Response Evaluation approach Based on in vivo CRISPR screening (DREBIC). The DREBIC is a major detour from conventional machine learning and statistical prediction models as it integrates functional screening based gene viability scores and basal expression levels to project cancer type- and mutation-specific drug sensitivity profiles. Using large-scale experimentally identified drug-response data from the Cancer Genome Project (CGP) and Cancer Cell Line Encyclopedia (CCLE) as a gold standard, DREBIC models trametinib response with high sensitivity and specificity across thousands of cancer cell lines. DREBIC identifies intrinsic fitness properties of various genotypes, enabling identification of therapeutic vulnerabilities of cancer-causing mutations with great precision. DREBIC will improve precision medicine by enabling patient-centered clinical decision-making for effective choice of chemotherapy.
Note: This abstract was not presented at the conference.
Citation Format: Mazhar ADLI. in vivo CRISPR screening enables precision medicine by identifying novel drug combinations and modeling anticancer drug sensitivity [abstract]. In: Proceedings of the AACR Precision Medicine Series: Opportunities and Challenges of Exploiting Synthetic Lethality in Cancer; Jan 4-7, 2017; San Diego, CA. Philadelphia (PA): AACR; Mol Cancer Ther 2017;16(10 Suppl):Abstract nr A08.
Abstract A09: Decomposing Oncogenic Transcriptional Signatures to Generate Maps of RAS/MAPK Cellular States
Authors: Kim Jongwook William , Hahn William C. , Mesirov Jill , Tamayo Pablo 
Published: December 2017

Abstract
The systematic sequencing of the cancer genome has provided a powerful framework for identifying genetic alterations in cancer. However, a deeper understanding of the functional consequences of these alterations is necessary to guide appropriate therapeutic strategies. Here, we describe Onco-GPS (OncoGenic Positioning System), a data-driven analysis framework, and associated experimental and computational methodology, to organize individual tumor samples with shared oncogenic alterations onto a reference map defined by their underlying cellular states. Using this approach, we generated series of RAS/MAPK sub-signatures that reflect known and novel downstream pathways. These sub-signatures were then used to classify KRAS and BRAF mutant cancers into sub groups or cell states, as represented in the novel visual paradigm OncoGPS map. The approach not only accurately classified three groups of BRAF mutant cancers that aligned with sensitivity to BRAF inhibitors, but also identified resistance mechanisms associated with each state. OncoGPS also identified four major cell states associated with KRAS mutant cancers. Further characterization of the four cell states showed that multiple molecular features representing epithelial-EMT states and activation of NF-κB pathway delineated two major axes of KRAS mutant cancers. In addition to the pathways and cell states defined in each group, the OncoGPS approach is able to identify effective drug combinations which was experimentally tested and confirmed. These results show that the Onco-GPS is an effective analytic framework to explore the complex landscape of oncogenic cellular states across cancers, and a powerful framework to summarize knowledge, establish relationships, and generate more effective disease models for research or as part of individualized precision medicine paradigms.
Citation Format: Jongwook William Kim, William C. Hahn, Jill Mesirov, Pablo Tamayo. Decomposing Oncogenic Transcriptional Signatures to Generate Maps of RAS/MAPK Cellular States [abstract]. In: Proceedings of the AACR Precision Medicine Series: Opportunities and Challenges of Exploiting Synthetic Lethality in Cancer; Jan 4-7, 2017; San Diego, CA. Philadelphia (PA): AACR; Mol Cancer Ther 2017;16(10 Suppl):Abstract nr A09.
Abstract A22: Synthetic lethality of cytolytic HSV-1 in cancer cells with ATRX and PML deficiency
Authors: Han Mingqi , Napier Christine E. , Frölich Sonja , Everett Roger D. , Cesare Anthony J. , Reddel Roger R. 
Published: December 2017

Abstract
In human somatic cells, telomeres shorten every cell division due to the end replication problem. Once reaching a critically short length, the cells will undergo permanent cell cycle arrest and become senescent. Cancer cells acquire unlimited proliferation ability by activation of a telomere maintenance mechanism, either the enzyme telomerase or the homologous recombination-based mechanism Alternative Lengthening of Telomeres (ALT). Cancers that utilize the ALT mechanism commonly are deficient for ATRX protein expression, are difficult to treat, and have a poor prognosis. We discovered that ICP0-null herpes simplex virus type 1 (HSV-1) was ten to one thousand-fold more effective in killing cancer cell lines that are ATRX-deficient. Sensitivity to mutant HSV-1 infection resulted from ATRX-dependent regulation of PML expression at both the transcriptional and post-transcriptional levels. Reduction of PML protein resulted in a concomitant reduction in PML nuclear bodies, which weakened the innate cellular immunity to viral infection. Infection of co-cultured primary and ATRX-null cancer cells revealed that mutant ICP0-null HSV-1 treatment preferentially killed ATRX-null cells. Our results suggest that mutant ICP0-null HSV-1 may have therapeutic benefit against ATRX-null cells. Moreover, these data provide an applicable approach for predicting, based on tumor ATRX or PML protein status, which tumors will respond to an oncolytic herpes virus.
Citation Format: Mingqi Han, Christine E. Napier, Sonja Frölich, Roger D. Everett, Anthony J. Cesare, Roger R. Reddel. Synthetic lethality of cytolytic HSV-1 in cancer cells with ATRX and PML deficiency [abstract]. In: Proceedings of the AACR Precision Medicine Series: Opportunities and Challenges of Exploiting Synthetic Lethality in Cancer; Jan 4-7, 2017; San Diego, CA. Philadelphia (PA): AACR; Mol Cancer Ther 2017;16(10 Suppl):Abstract nr A22.
Abstract A26: Prediction of synergistic anticancer drug combinations by integrating chemical and genetic screens
Authors: Jaiswal Alok , Gautam Prson , Tang Jing , Wennerberg Krister , Aittokallio Tero 
Published: December 2017

Abstract
Identification of effective drug combinations inhibiting multiple target genes that are essential for cancer cell survival is seen as an effective strategy to overcome drug resistance. Cellular pathways are often redundant, and network rewiring in the face of an assault promotes the emergence of resistant cells that contribute to clinical relapse. However, the number of possible drug-target combinations to investigate by conducting experiments is exponentially large and impractical, therefore warranting the need for systematic approaches to prioritize the most effective drug combinations. Here, we aimed to integrate large-scale drug screening, drug-target affinity knowledge and public RNAi screening datasets on a huge compendium of cancer cell lines to predict synergistic drug combinations. In a case study in an individual breast cancer cell line, MDA-MB-231, we identified drugs selectively active in this cell line compared to the background distribution. We find that target genes of active drugs and other genes involved in related cellular processes were also differentially essential in RNAi screening data. Further, we observe that the drug combinations of these selectively active drugs were synergistic. We propose a systematic approach for integrating chemical screening, drug target and cellular processes knowledge, and functional genetic screens to optimize drug combination testing efforts.
Citation Format: Alok Jaiswal, Prson Gautam, Jing Tang, Krister Wennerberg, Tero Aittokallio. Prediction of synergistic anticancer drug combinations by integrating chemical and genetic screens [abstract]. In: Proceedings of the AACR Precision Medicine Series: Opportunities and Challenges of Exploiting Synthetic Lethality in Cancer; Jan 4-7, 2017; San Diego, CA. Philadelphia (PA): AACR; Mol Cancer Ther 2017;16(10 Suppl):Abstract nr A26.